Drug Profile
Ivabradine sustained-release - Jiangsu Hengrui Medicine Co.
Alternative Names: Ivabradine hemisulfate sustained-release tablets - Jiangsu HengRui MedicineLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Benzazepines; Bradycardic agents; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic heart failure
Most Recent Events
- 05 Sep 2018 No development reported - Phase-II/III for Chronic heart failure in China (PO)